{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:17:03Z","timestamp":1790050623104,"version":"4.0.1"},"reference-count":13,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Brincidofovir (CMX001), a lipid conjugate of the acyclic nucleotide phosphonate cidofovir, is under development for smallpox treatment using \u201cthe Animal Rule,\u201d established by the FDA in 2002. Brincidofovir reduces mortality caused by orthopoxvirus infection in animal models. Compared to cidofovir, brincidofovir has increased potency, is administered orally, and shows no evidence of nephrotoxicity. Here we report that the brincidofovir half-maximal effective concentration (EC\n                    <jats:sub>50<\/jats:sub>\n                    ) against five variola virus strains\n                    <jats:italic>in vitro<\/jats:italic>\n                    averaged 0.11 \u03bcM and that brincidofovir was therefore nearly 100-fold more potent than cidofovir.\n                  <\/jats:p>","DOI":"10.1128\/aac.02814-14","type":"journal-article","created":{"date-parts":[[2014,6,24]],"date-time":"2014-06-24T02:08:33Z","timestamp":1403575713000},"page":"5570-5571","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":63,"title":["<i>In Vitro<\/i>\n                    Efficacy of Brincidofovir against Variola Virus"],"prefix":"10.1128","volume":"58","author":[{"given":"Victoria A.","family":"Olson","sequence":"first","affiliation":[{"name":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott K.","family":"Smith","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Foster","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Li","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Randall","family":"Lanier","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Gates","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence C.","family":"Trost","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger K.","family":"Damon","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.22.2127"},{"key":"e_1_3_3_3_2","first-page":"1","article-title":"Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC)","volume":"52","author":"Wharton M","year":"2003","unstructured":"WhartonMStrikasRAHarpazRRotzLDSchwartzBCaseyCGPearsonMLAndersonLJ. 2003. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 52:1\u201316.","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/v2122740"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303688"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01172-07"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.8.3153-3162.2005"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.3.678"},{"key":"e_1_3_3_9_2","volume-title":"Abstr. 15th Int. Conf. Antiviral Res.","author":"Huggins JW","year":"2002","unstructured":"HugginsJWBakerROBeadleJRHostetlerKY. 2002. Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox. Abstr. 15th Int. Conf. Antiviral Res., page A66, abstr 104."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1125134"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.5.1940-1946.2004"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01044-08"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.3390\/v3010047"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2007.08.003"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02814-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02814-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:50:16Z","timestamp":1645465816000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02814-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":13,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1128\/AAC.02814-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.02814-14","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718465738.793499297","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"2014-03-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-08-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}